Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics

Přední strana obálky
Glenn King
Royal Society of Chemistry, 11. 2. 2015 - Počet stran: 320

 This unique book will provide an up to date and comprehensive account of the potential of peptides and proteins from animal venoms as possible therapeutics. The pharmaceutical industry has become increasingly interested in biologics from animal venoms as a potential source for therapeutic agents in recent years, with a particularly emphasis on peptides. To date six drugs derived from venom peptides or proteins have been approved by the FDA, with nine further agents currently being investigated in clinical trials. In addition to these drugs in approved or advanced stages of development, many more peptides and proteins are being studied in varying stages of preclinical development. Topics covered include chemistry and structural biology of animal venoms, proteomic and transcriptomic approaches to drug discovery, bioassays, high-throughput screens and target identification, and reptile, scorpion, spider and cone snail venoms as a platform for drug development. Case studies are used to illustrate methods and successes and highlight issues surrounding administration and other important lessons that have been learnt from the development of approved therapeutics based on venoms. The first text to focus on this fascinating area and bridging an important gap, this book will provide the reader with essential and current knowledge on this fast-developing area. Venoms to Drugs will find wide readership with researchers working in academia and industry working in all medicinal and pharmaceutical areas.

 

Obsah

136
1
3779
37
8096
80
97128
97
129162
129
163203
163
204220
204
221244
221
245254
245
255274
255
275289
275
290305
290
306320
306
Autorská práva

Další vydání - Zobrazit všechny

Běžně se vyskytující výrazy a sousloví

O autorovi (2015)

Professor Glenn King has been working on animal venoms since 1996.He has extensive experience in the discovery, production, and structural and functional characterization of venom proteins, and is intimately aware of the issues surrounding their development as drugs and insecticides. In 2006, Professor King founded an agricultural biotechnology company, Vestaron Corporation, that is developing spider-venom peptides discovered in the lab as bioinsecticides.His current research is largely focussed on the development of venom peptides as analgesics for the treatment of chronic pain.

Bibliografické údaje